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Abstract -  This study evaluated the potential environmental concentrations of four cytostatic (also known 9 
as cytotoxic) drugs in rivers.  The antimetabolite 5-fluorouracil (5FU) and its pro-drug capecitabine were 10 
examined based on their very high use rates, cyclophosphamide (CP) for its persistence, and carboplatin for 11 
its association with the metal element platinum. The study combined drug consumption information across 12 
European countries, excretion, national water use, and sewage removal rates, to derive sewage effluent 13 
values across the continent.    There was found to be considerable variation in the popularity of individual 14 
cytostatic drugs across Europe, including a 28-fold difference in 5FU use and 15-fold difference in CP use .  15 
Such variation could have a major effect on the detection of these compounds in effluent, or river water.  16 
Overall, capecitabine and CP had higher predicted levels in effluent than 5FU, or carboplatin.  Predicted 17 
effluent values were compared with measurements in the literature and many non-detects could be 18 
explained by insufficient limits of detection.  Linking the geographic based water resources model GWAVA 19 
with this information allowed water concentrations throughout 1.2 million km of European rivers to be 20 
predicted.  The 90%ile (worst case) prediction indicated that, with the exception of capecitabine, >99% by 21 
length of Europe’s rivers would have concentrations below 1 ng/L for these cytostatic drugs.  For 22 
capecitabine 2.2% of river length could exceed 1 ng/L. 23 
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 26 
INTRODUCTION 27 
The discharge of pharmaceuticals in wastewater into the aquatic environment has been a source of 28 
discussion and concern in scientific and regulatory circles now for well over a decade [1, 2].  Chemotherapy 29 
drugs in the group known as cytostatic, cytotoxic or antineoplastic (hereafter described as cytostatic) often 30 
feature on lists of pharmaceuticals of concern which we discharge into our river systems [3, 4].  These 31 
compounds are now an increasingly popular subject of environmental research and discussion [5-7].  There 32 
is relatively little information available on the toxicity of cytostatic drugs to aquatic organisms.  The 33 
information that is available suggests that cytostatic drugs are not very toxic to a variety of aquatic 34 
organisms [8-10].  However, long term exposure studies particularly with fish and including more than one 35 
generation have not yet been conducted.  Therefore, it is premature to conclude that environmental 36 
concentrations of cytostatic drugs pose no risk to aquatic organisms 37 
A greater focus has been on their potential to harm humans through water recycling.  This scenario 38 
is where rivers are used both to receive sewage effluent and as a source of drinking water.  A significant 39 
difference between humans and aquatic wildlife is that the former are protected by a range of water 40 
purification technologies [11, 12].  Whilst this is reassuring, there are some grounds for suggesting some of 41 
the water soluble cytostatic drugs like cyclophosphamide may still survive ozonation and pass through into 42 
drinking water [13].  Many would still consider that this is not a concern, as even the most pessimistic 43 
predictions indicate exposure to these drugs would still be considerably below levels of concern [14, 15].  44 
Another angle is that the unborn child in the womb would be particularly vulnerable to inadvertent exposure 45 
to cytostatic drugs, due to their teratogenic potential [16].  However, a comprehensive study indicated that 46 
exposure during the foetal development phase of the second trimester onwards carried little risk of harmful 47 
effects to the unborn child [17].  Nevertheless, exposure in the embryogenesis period, which occurs in the 48 
first trimester (approximately the first 12 weeks following conception) could lead to a range of 49 
malformations [18]. 50 
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Key to any assessment of the risks involved are the concentrations likely to be found in surface, or 51 
drinking water.  A number of studies have been carried out to detect and analyse cytostatic drugs in sewage 52 
effluent and surface waters in recent years, with mixed levels of success.  This is not an unreasonable 53 
exercise given the common administration of chemotherapy in the outpatient departments of most city 54 
hospitals [7].  However, a high proportion of these studies failed to find the selected cytostatic drugs [19-25] 55 
leaving the reader not knowing whether the drug was actually not used in that city/country, was successfully 56 
eliminated in sewage treatment, or present but at a concentration below the limit of detection (LOD)? 57 
A number of authors have reviewed the considerable number of cytostatic drugs used in 58 
chemotherapy whose discharge might have harmful consequences  for the environment [5-7].  Some are 59 
used more frequently than others as they are associated with treating the most common cancers, or used 60 
for a diverse range of cancers.  This study has selected four cytostatic drugs for further study, based on 61 
either their high consumption, their persistence in the environment, or novelty.  The cytostatic drug 2-62 
[bis92-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide better known as 63 
cyclophosphamide (CP), is a commonly used alkylating agent dating back to the late 1950s.  It is typically 64 
given intravenously (IV) although low doses may be given orally.  It needs to be metabolised by cytochrome 65 
P450 enzymes in the liver to liberate alkylating metabolites such as nor-nitrogen mustard, which can cross-66 
link DNA [26-28].  It has been used to treat a range of cancers including brain, bone and leukemia as well as 67 
some autoimmune diseases [26].  This drug has received considerable interest from environmental scientists 68 
over the years due to its apparent persistence [29-31]. 69 
  The cytostatic drug cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) also known as 70 
carboplatin, is a relatively recent cytostatic drug with clinical trials carried out successfully in the mid 1980s 71 
[32].  Carboplatin is always administered via IV.  The major cytostatic activity of carboplatin is binding with 72 
DNA to form intra-strand crosslinks and adducts that cause changes in the conformation of the DNA and 73 
affect DNA replication.  Its use has been promoted since it has much less side effects on patients than other 74 
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Pt containing drugs such as cisplatin [32].  As a representative of the Pt containing group of cytostatic drugs, 75 
it may be a source of Pt contamination of the aquatic environment [33]. 76 
The antimetabolite 5-fluorouracil (5FU) and its pro-drug capecitabine are often found near the top of the 77 
consumption list for many countries.  Following the observation that cancer tissues incorporated uracil much 78 
more than non-malignant tissues, 5-fluorouracil (5FU) was synthesised as an antimetabolite chemotherapy 79 
drug back in 1957 [34].  It is typically given to the patient via intravenous delivery.  Partly due to the need to 80 
give the drug via the intravenous route, it appears to be less popular than its pro-drug capecitabine, which 81 
can be given orally.  Indeed 5FU does not now appear to be used at all in Finland.  The 5FU pro-drug pentyl 82 
[1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-pyrimidin-4-yl]carbamate, commonly 83 
known as capecitabine is a drug popularly used for treating colorectal and breast cancers [35].  Unlike 5FU, it 84 
is well absorbed when taken orally and in the liver is metabolised through a series of intermediates to form 85 
5’-deoxy-5-flourouridine, which is then converted to 5FU by the thymidine phosphorylase enzyme.  This 86 
enzyme tends to be over expressed in tumour tissue [36], thus giving capecitabine greater selectivity than 87 
5FU.   88 
This study attempted to predict the range of possible cytostatic drug concentrations in sewage effluent 89 
and surface waters for the different countries in the European Union.  The method used publically available 90 
consumption data, literature data on human excretion values and sewage removal rates.  The major 91 
refinement on previous studies was the use of varying national consumption values and wastewater 92 
discharge values.  The following objectives were addressed: 93 
• How different are national per capita cytostatic drug consumption values? 94 
• What range of concentrations in effluents might be expected given different per capita wastewater 95 
discharge rates? 96 
• How well do national predicted values correspond to published measured concentrations? 97 
• To predict surface water concentrations throughout Europe using a geographic based water quality 98 
model. 99 
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MATERIALS AND METHODS 100 
Assessing per capita consumption rates 101 
The approach to estimating effluent concentrations takes the drug consumption per capita for a 102 
specific nation less that prevented from being excreted as the free parent compound less that removed in 103 
sewage treatment.  The effluent concentration is then calculated by dividing this figure by the per capita 104 
wastewater discharge for that nation: 105 
 106 
W= (C−E−S)
D
 107 
 108 Where C is consumption of the drug as ng/cap/d; E is the amount of the drug that is not excreted 109 
(ng/cap/d); S is the amount of the drug that is prevented from escaping into sewage effluent (ng/cap/d); D is 110 
the diluting volume of wastewater as L/cap/d; and W is the effluent concentration as ng/L. 111 
The most critical part of any model to assess concentrations of human derived chemicals in water is 112 
obtaining accurate information on usage.   Fortunately, there are some national annual consumption data on 113 
cytostatic drugs which are publically available.  These can be interrogated to assess a per capita consumption 114 
value, given the population of the country at that time (Table 1).  The data available ranged from as recent as 115 
one year ago to fifteen years old.  Data on drug consumption for England was a summary of the responses 116 
from the major 34 health trusts, with the data originally cited as mg/1000 people over a 6 month period in 117 
2005 [37]. 118 
Assessing per capita excretion rates and sewage removal rates 119 
The next stage in a modelling environmental concentrations of a pharmaceutical is to ascertain how 120 
much of the parent compound is excreted unchanged by the patient.  Unsurprisingly, not all humans are the 121 
same in their excretion behaviour, with such factors as age, health and co-medication all influencing the 122 
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percentage excreted.  It is therefore advisable to survey as wide a range of literature as possible on excretion 123 
rates before arriving at a mean value.  Similarly, natural variations in sewage performance can influence 124 
pharmaceutical removal rates in treatment.  Unfortunately, the literature on removal in sewage treatment 125 
for many of the cytostatic drugs is still meagre and this must be considered a weak point in modelling these 126 
compounds. 127 
CYCLOPHOSPHAMIDE  In the seven references covering 74 patients receiving CP there was a 128 
relatively small range in % CP excreted reported over a 24 h period (Table 2).  The amount of original CP 129 
excreted unchanged ranged from 11 to 20% with a weighted mean of 15.9%.  Thus, these values can be used 130 
as upper, lower and mean excretion rate values.  There is considerable agreement that CP is a persistent 131 
compound in both sewage and river water [29-31].  Thus, a simple prediction of CP concentration in sewage 132 
effluent can be made, assuming the per capita wastewater discharge volume is known, and no significant 133 
attenuation occurs after excretion.   134 
CARBOPLATIN  A proportion of the carboplatin taken by the patient (normally intravenously) is 135 
excreted unchanged and several studies have attempted to measure the % of the parent molecule in the 136 
urine over a 24 h period.  Some of the reports can at first be misleading as they only measure platinum, but 137 
it is possible to identify several references where the parent compound itself was measured in the urine.  In 138 
the five references covering 50 patients, the amount of original carboplatin excreted unchanged ranged 139 
from 14 to 69% with a weighted mean of 31.7% (Table 2). 140 
  There are few studies on the fate of carboplatin in the environment but a number of medical 141 
researchers have noted that it is not persistent in urine.  The only reference which provides data that can be 142 
used on this topic was one where 5 activated sludge plants were studied and an average elimination from 143 
the effluent of 72% recorded from a range of 59-85% [38].   144 
5-FLUOROURACIL  As might be expected with a polar drug, the major route of excretion is in the 145 
urine, with fecal excretion believed to be unimportant [39].  A potential complication with choosing an 146 
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appropriate excretion rate is that some treatments, such as those combined with eniluracil, give markedly 147 
higher urinary excretion of unchanged 5FU [40, 41].  However, the most used combination therapies appear 148 
to be with methotrexate, or leucoverin [34], which don’t seem to have a dramatic effect on the 5FU amount 149 
excreted in the urine.  Also excretion of unchanged 5FU is much higher when given orally, which probably 150 
explains the preference for IV use [42]. It was possible to identify four references where the parent 151 
compound was measured in the urine in treatments without eniluracil.  In the four references covering 32 152 
patients examined, there was a fairly wide range in % excreted reported (Table 2).  The amount of original 153 
5FU excreted unchanged ranged from 2 to 39%, with a weighted mean of 4.6%.  Thus, these values could be 154 
used as a upper, lower and mean excretion rate values.  However, before moving on to national predictions 155 
for 5FU in sewage effluent, the contribution from patients taking capecitabine also needs to be taken into 156 
account.  The amount of 5FU excreted from patients receiving capecitabine ranged from 0.5 to 0.8%, with a 157 
weighted mean of 0.7% (Table 2).   158 
There have been a number of studies on the biodegradability of 5FU which give the general 159 
impression that significant removal in sewage treatment is probable (Table 3).  Removal would be strongly 160 
dependent on biodegradation, as sorption to sewage particles appears to be low [43].  However, the studies 161 
were typically carried out at high concentrations with adapted microbial populations over long time periods 162 
and probably at room temperature, circumstances that may well not be typical of operational STPs in 163 
Europe.  Of these studies, those reported by Kiffmeyer et al. (1998) [29] and Mahnik et al. (2007) [43] 164 
probably come closest to replicating the activated sludge environment most typical of European wastewater 165 
treatment, albeit at µg/L rather than the ng/L concentrations which might have been more realistic.  These 166 
studies were most probably carried out at room temperature, which would tend to overestimate removal in 167 
winter.  Given a probable range of 90-99% removal from these studies, a removal rate of 95% was selected.  168 
To estimate 5FU concentration in sewage effluent, the predicted value deriving from both 5FU consumption 169 
(following excretion and removal in sewage treatment) and from capecitabine consumption (with its unique 170 
excretion of 5FU and sewage removal) must also be included. 171 
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CAPECITABINE  Fortunately, a number or references exist where unchanged capecitabine was 172 
measured in the urine following administration to patients (Table 2).  The amount of capecitabine excreted 173 
unchanged from patients receiving capecitabine ranged from 2.6 to 3.4%, with a weighted mean of 3.1%.   174 
However, it is very difficult to predict the fate of capecitabine in sewage, as no references can be found on 175 
the topic other than some high concentration OECD laboratory studies carried out by Roche [15], where it 176 
was described as slowly degradable.  For this modelling exercise it was assumed 50% would be removed in 177 
sewage treatment. 178 
The summary of deduced excretion and removal rates for all the drugs is shown in Table 4.  Given 179 
consumption, excretion and sewage removal information, all that remains is a national per capita 180 
wastewater discharge value in order to predict an effluent concentration.  A per capita wastewater discharge 181 
value was assumed to be the same as the national per capita water use value. Per capita water use values 182 
are provided in a number of reports, including Eurostat from the EU, Environment Agency of England and 183 
Wales, UN Development Programme and Environment Canada although they don’t always agree with one 184 
another!  Where available, the Eurostat values have been used in this study.  Such predicted values are likely 185 
to be conservative since many STP also receive industrial waste which would further dilute the wastewater 186 
and hence lower the concentrations. 187 
European river water modelling 188 
To examine potential concentrations of these cytostatic drugs throughout European surface waters, 189 
the geographic-based water resources model GWAVA was used [44].  The geographic database of this model 190 
includes the location and size of the human European population and their association with sewage 191 
treatment plants (STPs).  The flows through these STPs are incorporated with other flows and abstractions 192 
into the hydrological model.  The hydrology is driven by monthly climate over the period 1970-2000.    The 193 
chemical inputs of per capita drug consumption and removal in sewage were provided by this study.  The 194 
model calculates the water concentrations through a series of 177,470 grid squares of approximately 6 x 9 195 
km (5 by 5 Arc minutes) dimensions.  GWAVA summates all the inputs and dilutions within a cell to give a 196 
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value at the downstream ‘outflow’ location of that cell.  This does not necessarily represent the highest 197 
concentration that could occur at some point within that cell.  However, at the scale of the European 198 
continent portrayed by the model, this scale is considered to be the best compromise and will reveal the 199 
exposures most likely to be faced by the majority of aquatic wildlife. 200 
The main variables in modelling these cytostatics drugs were, therefore, consumption, excretion, 201 
sewage removal and dilution (Table 4).  GWAVA can also modify the concentrations by including a water 202 
column attenuation rate, however, in the absence of such information for these compounds they were 203 
assumed to be conservative once in the rivers. 204 
RESULTS AND DISCUSSION 205 
Predicted European sewage effluent concentrations 206 
Although the incidence of different cancers are unlikely to be very different across European 207 
countries, the selection of drugs to treat these diseases does vary in popularity.  Indeed the popularity of 208 
certain cytostatics can vary across different regions in the same country [37].  For example,  209 
cyclophosphamide (CP) is more than twice as popular in Sweden than any other European country for which 210 
data were obtained, with a fifteen-fold difference in possible use across Europe (Table 1, Figure 1).  There is 211 
an eight-fold difference in carboplatin consumption between the European countries examined, whilst for 212 
capacitabine this is a four-fold difference (Table 1, Figure 1).  The greatest variation is with 5FU with a 213 
twentyeight-fold difference in use (Figure 1).  The predicted mean effluent concentrations ranged from 2 to 214 
40 ng/L for CP, 0.8 to 2.5 ng/L for carboplatin, 0.3-2.5 ng/L for 5FU, and 8.5-87 ng/L for capecitabine, which 215 
reflect the original consumption preferences and differences in national per capita wastewater discharge 216 
(88-230 L/cap/d) (Figure 2).   217 
These model predictions suggest chemists wishing to monitor CP in sewage effluent must achieve 218 
LODs below 1.7 ng/L, expect a European mean concentration of 11 ng/L and travel to Sweden to find the 219 
highest concentrations in effluent.  Those wishing to monitor carboplatin in sewage effluent must achieve 220 
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LODs below 0.8 ng/L and expect a European mean concentration of 2.4 ng/L.  Carboplatin is not recorded on 221 
the medical databases for Netherlands, Norway and Finland and so may not be officially prescribed in those 222 
countries.  Those wishing to monitor 5FU in sewage effluent must achieve LODs below 0.3 ng/L expect a 223 
European mean concentration of 1.0 ng/L, with the highest predicted value of 2.5 ng/L being found in the 224 
Czech Republic.  Those wishing to monitor capecitabine in sewage effluent must achieve LODs below 8.5 225 
ng/L expect a European mean concentration of 29.3 ng/L, with the highest predicted value of 87 ng/L being 226 
found in the Czech Republic. 227 
Comparing predicted and measured effluent concentrations 228 
 A major objective of this study was to compare and corroborate measured cytostatic drug 229 
concentrations with those predicted here.  Thirteen studies on CP in sewage effluent were examined.  The 230 
per capita wastewater discharge values used to predict the results were either calculated from the authors 231 
own data, Eurostat 2012, UN 2006, or Environment Canada.  Where it was not known, the mean European 232 
per capita consumption for CP was used. Of the six references which report non detects, three can be 233 
explained simply by having LODs above the predictable levels (Table 5).  Where the LOD was below the 234 
predicted concentration and yet still no detection made [19, 22, 23], the possibility still exists that 235 
wastewater flow was greater than expected on that sampling day.  Of the 8 detections, five of the 236 
predictions using the method described in this paper were within an order of magnitude of those reported. 237 
Three studies were found were chemists tried to measure 5FU in sewage effluents in Spain, 238 
Switzerland and the USA, but these resulted in no detections [25, 45, 46].  The reported LODs were 15-21 239 
ng/L, but using the prediction method described above, the mean effluent values would be expected to be 240 
0.6-1.0 ng/L which would appear to explain their failures.  No studies on carboplatin, or capecitabine, 241 
concentrations in domestic sewage effluent could be found. 242 
Predicting European river concentrations 243 
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The GWAVA model is providing predictions for 1.2 million km of European rivers receiving the waste 244 
from 602.8 million people so that a single run of the model with its 177,000 grid squares and 31 years of 245 
climate data generates 66 million results per chemical.  All the variables discussed will play a role, but it is 246 
clear that the most important factor in predicting correctly river concentrations apart from consumption is 247 
dilution (Table 4).  Different interpretations on human excretion, or sewage removal rates could change the 248 
values by up to 20-fold but dilution could change the values by up to 1000-fold!  The results from model runs 249 
can be displayed in a number of different ways, such as a map showing the 50%ile concentrations across 250 
Europe for CP based on a mean excretion rate and mean sewage treatment removal (Figure 3).  This is 251 
broadly equivalent to the concentration that would be recorded at a median flow for that part of a river and 252 
so might represent the typical exposure for surface waters.     In this case the CP hot spots reflect not just the 253 
geography and hydrology of Europe, but also the popularity of the drug.  This helps to explain the relatively 254 
low predicted concentrations in Italy compared with southern Sweden (Figure 3).  The results can also be 255 
displayed as cumulative frequency curves, such as all the 90%ile concentration values for all the cells based 256 
on the highest possible human excretion rates and lowest sewage treatment removal (Figure 4).  These 257 
predictions could be considered as potential worst case river concentrations such as might be associated 258 
with low summer flows.  In this river scenario, the simulations indicate that 99% of European river locations 259 
would be below 0.2 ng/L  for carboplatin and below 0.6 ng/L for 5FU.  With CP only 0.1% of locations could 260 
exceed 1 ng/L, whilst for capecitabine 2.2% could exceed 1 ng/L in rivers (with 0.2% in the 3-41 ng/L 261 
bracket).  Of course it should be remembered the highest possible concentrations would be that of undiluted 262 
sewage effluent (Figure 2).   263 
CONCLUSIONS 264 
Overall, the availability of fairly recent drug consumption data from reliable sources and excretion 265 
data from the medical literature has put this model in a strong starting position.  The potential impact on the 266 
modelling of differences in consumption, human excretion, sewage removal and dilution range from only 267 
1.3-fold to 1000-fold (Table 4).  Getting good information on all of these factors are of course important for 268 
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precision but here differences in consumption and hydrology are the most critical to get right.  The good 269 
correlation between values predicted in this study and those observed in sewage effluent for CP give 270 
grounds for encouragement.  We anticipate further refinement of the model will be possible in the future as 271 
more information on the fate and behaviour of these compounds becomes available.   272 
Returning to the original objectives of the study we found there was a surprising difference in 273 
popularity of these cytostatics drugs across European nations, which can be up to 28-fold.  The predicted 274 
mean effluent concentrations ranged from 2 to 40 ng/L for CP, 0.8 to 2.5 ng/L for carboplatin, 0.3-2.5 ng/L 275 
for 5FU, and 8.5-87 ng/L for capecitabine.  In the majority of cases, where data is available, it is possible to 276 
predict CP concentrations in sewage effluent to within an order of magnitude of that observed.  By linking 277 
with the geographic based water quality model it is expected that the majority of European rivers would 278 
have concentrations below 1 ng/L for these cytostatics drugs 279 
The predicted river concentrations are considerably below concentrations so far reported to have 280 
effects on aquatic wildlife [8, 9].  As even in the 90%ile prediction around 80% of European surface waters 281 
for these drugs were largely below 0.1 ng/L, there does not appear to be any widespread threat to European 282 
aquatic wildlife based on our current knowledge.  The issue of water abstraction for drinking water and 283 
foetal health may still require further research.  Given its potentially high effluent concentrations and good 284 
oral absorption by humans, capecitabine certainly seems worthy of further environmental research. 285 
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Table 1. National cytostatic drug consumption information normalised from annual use to per capita using 
the national population at the time of the survey cyclophosphamide (CP), carboplatin (Carb), 5-
fluorouracil (5FU) and capecitabine (Cap) 
Country Source Year CP use 
(mg/cap/d) 
Carb use 
(mg/cap/d) 
5FU use 
(mg/cap/d) 
Cap use 
(mg/cap/
d) 
Germany http://www.umweltbundesamt.de/u
ba-info-medien/dateien/3744.htm 
2002 0.0084 0.0034 0.0519 0.1838 
France AFSSAPS quoted by [5] 2008 0.0129 0.0035 0.0730 0.2164 
England UK Dept of Health quoted by [37] 2005 NA* 0.0021 NA 0.1335 
Italy OsMed 2011 2011 0.0034 NA 0.0032 0.1476 
Netherlands http://www.gipdatabank.nl/ 2009 0.0027 NA 0.0185 0.3938 
Austria Drug data from [47] 1997 0.0134 0.0010 0.0410 Not 
used  
Denmark http://www.medstat.dk/statistics/#t
abs-2 
2009 0.0057 0.0010 0.0026 0.3882 
Switzerland IHA-IMS quoted by [25] 2002 0.0127 NA 0.0303 0.1701 
Sweden Apotekensservice at 
http://www.apotekensservice.se and 
Tandvårds- och 
Läkemedelsförmånsverket TLV; at 
http://www.tlv.se/beslut/sok/lakem
edel/ 
2010 0.0357 0.0015 0.0302 0.2267 
Norway Norwegian Prescription Database at 
http://www.norpd.no/ or 
http://www.legemiddelforbruk.no 
2010 0.0092 NA 0.0270 0.1167 
Finland Data from Kela (at 
http://www.kela.fi and 
http://asiointi.kela.fi/laakekys_app) 
2010 0.0023 NA 5-FU not 
used 
0.3728 
Czech 
Republic 
Data from SUKL at 
http://www.sukl.cz/modules/medica
tion/search.php 
 
2011 0.0102 0.0084 0.0198 0.4937 
European 
mean value 
  0.0104 0.0030 0.0297 0.2585 
*NA information not available or not found  
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Table 2. Proportion of cytostatic drug excreted unchanged by patients  
Drug excreted 
Reference 
No 
patients mean age Cause 
Dose 
(g/d) Excretion %* 
Cyclophosphamide [28]  2 NG** NG 1-2.6  14.5 
 [48]  12 43 autoimmune 0.8-1.7 19 
 
[49]  16 
26 bone 
marrow 
3.5-4.2 
14 
 
[50]  4 
48 breast 
cancer 
4.2 
16.5 
 [51]  19  NG 4.2 14 
 [27]  6 NG autoimmune 1.7 11 
 [52]  15 44 NG 6.8-10 20 
Carboplatin [32]  14 NG* healthy 
volunteers 
0.03-0.9 32 
 
[53] 
 3 59 multiple 
cancers 
0.27-
0.68 
69 
 
[51] 
 19 30 bone 
marrow 
3.9 14 
 
[54] 
 7 55 ovarian 
cancer 
0.49-
0.63 
41 
 [55]  7 64 lung cancer 0.17 54 
5FU [56]  1 NG Colon 1.0 39 
 [57]  1 NG Colorectal 
cancer 
0.75 11 
 [39]  8 NG NG* 0.85 6.5 
 [42]  22 61 Largely 
colorectal 
cancer 
3.9 2.0 
5FU from 
capecitabine 
[36]  7 59 Range of 
cancers 
2.0 0.5 
 [58]  13 56 Range of 
cancers 
2.1 0.7 
 [59]  23 63 Range of 
cancers 
2.0 0.7 
 [60]  60 60 Colorectal 
cancer 
4.25 0.8 
Capecitabine [36]  7 59 Range of 
cancers 
2.0 2.9 
 [58]  13 56 Range of 
cancers 
2.1 2.6 
 [59]  23 63 Range of 
cancers 
2.0 2.7 
 [60]  60 60 Colorectal 
cancer 
4.25 3.4 
*Where two excretion values were given for separate days of treatment, the average value is reported 
**NG Information not provided  
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Table 3. Review of fate studies with 5FU in sewage environments 
Reference Environment Concentration 
(µg/L) 
Removal (%) Time period Comment 
[61] Sewage inoculums 
in OECD tests 
9000-854,000 No removal  High concentrations 
were inhibitory? 
[29] Lab act. sludge pilot 
plant 
3,000 96-100% from 2 
d onwards 
14 d Population became 
adapted? 
[43] Act. Sludge 
microcosm 
5 92-98% (90% at 
15 h) 
24 h Replication not 
reported 
[62] Hospital 
biologically live 
storage tank 
15-98 100% Approx. 24 h Biological treatment 
conditions unclear 
[63] Sewage inoculated 
biofilm column 
10 97 200 d 
(hydraulic 
residence 
time 8 h) 
Attempting to 
replicate soil aquifer 
treatment 
[64] Growth medium 
inoculated with act. 
sludge 
1-50 50 50 d A weak inoculum 
possibly changed 
from usual sludge 
community 
structure 
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Table 4.  Summary of variables and their potential effects on the predictive modelling of 
cyclophosphamide (CP), carboplatin (Carb), 5-fluorouracil (5FU) and capecitabine (Cap) 
Drug Range in 
consumption 
across EU 
Weighted 
mean and 
range in 
patient 
excretion 
values (%) 
Effect on 
sewage 
influent 
conc. 
Mean and 
range in 
sewage 
treatment 
removal (%) 
Effect on 
sewage 
effluent 
conc. 
Range in 
European 
dilution 
potential 
(m3/cap/d) ** 
Effect on 
river conc. 
CP 15-fold 15.9 (11-20) 1.8-fold 0 No 
difference 
2.8 - 2.7∙103 1000-fold Carb 8-fold 31.7 (14-69) 5-fold 72 (59-85) 2.7-fold 
5FU 28-fold 4.6 (2-39)* 19-fold 95 (92-99) 8-fold 
Cap 4-fold 3.1 (2.6-3.4) 1.3-fold 50 (25-75) 3-fold 
*5FU has a weighted mean of 0.7 and a range of 0.5-0.8% when excreted by patients taking capecitabine 
**10%ile to the 90%ile of dilution values calculated on a cell-by-cell basis using 1970-2000 average river discharge  
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Table 5. Comparing literature measured cyclophosphamide with predicted values for sewage effluents  
Reference Location 
Calculated 
water use 
L/cap/d 
LOD 
(ng/L) 
Reported 
value 
(ng/L) 
Predicted 
value 
(ng/L) 
Comments 
on 
simulation 
Thomas et al 2007 VEAS STP Oslo 722 2 <2  2.0 Acceptable 
Kanda et al 2003 6 x STP UK 160 23 <23  10.4 Agree 
Yin et al 2010 7 x STP beijing, 
China 
160 0.8 8.5-14.5  10.4 Agree 
Buerge et al 2006 Zurich STP 630 0.3 2.1-4 3.3 Agree 
Metcalfe et al 2003 18 x STP Canada 527 100 <100 3.2 Agree 
Garcia-Ac et al 
2011 
Montreal STP 
Canada 
329 0.5 12 5.1 Agree 
Hua et al 2006 Windsor STP 
Canada 
329 1 2.5-4 5.1 Agree 
Llewellyn et al 2011 ASP H UK 200 0.04 0.2 8.3 Fail 
 Biol filt L UK 300 0.12 3.6 5.5 Agree 
Calamari et al 2003 Po & Lambro R, 
Italy 
203 0.01 <0.01  1.4 Fail 
Zuccato et al 2005 9 x STP Italy 203 NA* 0.6 2.7 Acceptable 
Martin et al 2011 1 x STP Spain 153 1.7-2.3 0.6 10.9 Fail 
Gomez-Canela et al 
2012 
3 x STP Spain 153 3.1 <3.1 10.9 Acceptable 
Busetti et al 2009 1 x STP Australia 480 125 <125 3.5 Agree 
*NA Information not provided  
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Figure 1.  Variations in per capita cyclophosphamide (CP), carboplatin (Carb), 5-fluorouracil (5FU) and 
capecitabine (Cap) consumption between different European nations.  Note these values do not all come 
from the same year. 
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Figure 2.  Predicted mean cyclophosphamide (CP), carboplatin (Carb), 5-fluorouracil (5FU) and capecitabine 
(Cap) concentrations in sewage effluent for European nations taking into account differing national per 
capita wastewater discharge values. 
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Figure 3. Predicted cyclophosphamide (CP) concentrations in surface water based on mean excretion rate, 
mean sewage treatment removal, and 50%ile flow across the European Continent taking into account 
differing national per capita consumption and wastewater discharge values from the GWAVA model.  
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Figure 4. Predicted 90%ile concentrations for cyclophosphamide (CP), carboplatin (Carb), 5-flourouracil (5FU) 
and capecitabine (Cap) in surface water assuming high excretion rates and low sewage treatment removal 
across the whole European Continent from the GWAVA model plotted as cumulative frequency curves. 
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